By Katherine Hamilton
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
The Copenhagen, Denmark, biotechnology company said Monday Johnson & Johnson has decided it won't exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38, which is designed to treat people with certain blood cancers.
Genmab will not pursue further clinical development of the drug, it said, after evaluating the data, market landscape and its own portfolio prioritization.
Genmab had provided Johnson and Johsnon with data from a clinical proof-of-concept study for HexaBody-CD38 to treat multiple myeloma. Preliminary data demonstrated an overall response rate of 55%, while the rate of very good partial response or better was 29% and complete response or better was 7%.
Johnson & Johnson's decision does not impact Genmab's 2025 financial guidance, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 10, 2025 10:43 ET (14:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。